The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody‐secreting cells
Open accessAbstract
Objective: To investigate the hypothesis that proteasome inhibition may have potential in the treatment of SLE, by targeting plasmacytoid dendritic cells (PDCs) and plasma cells, both of which are critical in disease pathogenesis. Methods: Lupus‐prone mice were treated with the nonselective proteasome inhibitors carfilzomib and bortezomib, the immunoproteasome inhibitor ONX 0914, or vehicle control. Tissue was harvested and analyzed by flow cytometry using standard markers. Nephritis was monitored by evaluation for proteinuria and by histologic analysis of kidneys. Serum anti–double‐stranded DNA (anti‐dsDNA) levels were measured by enzyme‐linked immunosorbent assay (ELISA), and total IgG and dsDNA antibody‐secreting cells (ASCs) by enzyme‐linked immunospot assay. Human peripheral blood mononuclear cells or mouse bone marrow cells were incubated with Toll‐like receptor (TLR) agonists and proteasome inhibitors, and interferon‐α (IFNα) levels were measured by ELISA and flow cytometry. Results: Early treatment of lupus‐prone mice with the dual‐targeting proteasome inhibitors carfilzomib or bortezomib or the immunoproteasome‐specific inhibitor ONX 0914 prevented disease progression, and treatment of mice with established disease dramatically abrogated nephritis. Treatment had profound effects on plasma cells, with greater reductions in autoreactive than in total IgG ASCs, an effect that became more pronounced with prolonged treatment and was reflected in decreasing serum autoantibody levels. Notably, proteasome inhibition efficiently suppressed production of IFNα by TLR‐activated PDCs in vitro and in vivo, an effect mediated by inhibition of both PDC survival and PDC function. Conclusion: Inhibition of the immunoproteasome is equally efficacious as dual targeting agents in preventing lupus disease progression by targeting 2 critical pathways in disease pathogenesis, type I IFN activation and autoantibody production by plasma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jego, G., Palucka, A. K., Blanck, J.-P., Chalouni, C., Pascual, V., & Banchereau, J. (2003) · Immunity · doi:10.1016/s1074-7613(03)00208-5 · Cited by 1,067
Cited by
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Huber, E. M., Basler, M., Schwab, R., Heinemeyer, W., Kirk, C. J., Groettrup, M., & Groll, M. (2012) · Cell · doi:10.1016/j.cell.2011.12.030 · Cited by 483
Self-citationAlexander, T., Sarfert, R., Klotsche, J., Kühl, A. A., Rubbert-Roth, A., Lorenz, H.-M., Rech, J., Hoyer, B. F., Cheng, Q., Waka, A., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206016 · Cited by 368
A Practical Review of Proteasome Pharmacology
Thibaudeau, T. A., & Smith, D. M. (2019) · Pharmacological Reviews · doi:10.1124/pr.117.015370 · Cited by 344
Redefining lupus nephritis: clinical implications of pathophysiologic subtypes
Yu, F., Haas, M., Glassock, R., & Zhao, M.-H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.85 · Cited by 340
Metadata
- Authors
- Ichikawa, H. T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B. I., Kirk, C. J., Looney, R. J., & Anolik, J. H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-01-27
- Volume
- 64
- Issue
- 2
- Pages
- 493-503
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2103402364
- Cited by
- 244
- References
- 1
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody‐secreting cells. https://app.cochat.ai/papers/10.1002/art.33333
- The paper
- Ichikawa, H. T., Conley, T., Muchamuel, T., Jiang, J., Lee, S., Owen, T., Barnard, J., Nevarez, S., Goldman, B. I., Kirk, C. J., Looney, R. J., & Anolik, J. H. (2012). Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody‐secreting cells. Arthritis & Rheumatism. https://doi.org/10.1002/art.33333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.